Remdesivir
- Generic Name
- Remdesivir
- Brand Names
- Veklury
- Drug Type
- Small Molecule
- Chemical Formula
- C27H35N6O8P
- CAS Number
- 1809249-37-3
- Unique Ingredient Identifier
- 3QKI37EEHE
- Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp)...
- Indication
Remdesivir is indicated for the treatment of adult and pediatric patients 28 days of age and older and weighing at least 3 kg for coronavirus disease 2019 (COVID-19) infection requiring hospitalization. It is also indicated for the treatment of non-hospitalized patients with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, ...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Melbourne
- Target Recruit Count
- 2200
- Registration Number
- NCT04483960
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺Western Health, St Albans, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 59
- Registration Number
- NCT04431453
- Locations
- 🇺🇸
Johns Hopkins Children's Center, Baltimore, Maryland, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 649
- Registration Number
- NCT04409262
- Locations
- 🇪🇸
Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇺🇸Baylor Scott & White Medical Center - Irving, Irving, Texas, United States
🇧🇷Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- ViralClear Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04410354
- Locations
- 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸HCA Houston Healthcare Medical Center, Houston, Texas, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-03-14
- Target Recruit Count
- 1033
- Registration Number
- NCT04401579
- Locations
- 🇺🇸
Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States
🇺🇸University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States
🇺🇸University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States
COVID-19 and Anti-CD14 Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2023-06-26
- Target Recruit Count
- 49
- Registration Number
- NCT04391309
- Locations
- 🇺🇸
Sarasota Memorial Health Care System, Sarasota, Florida, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 24
- Registration Number
- NCT04385719
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections
- Conditions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 84
- Registration Number
- NCT04365725
- Locations
- 🇫🇷
Hôpital Cochin, Paris, France
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 500
- Registration Number
- NCT04351724
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Tirol, Austria
🇦🇹Wilhelminenspital, Vienna, Austria
🇦🇹SMZ Ost Donauspital, Vienna, Austria
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
- Conditions
- Interventions
- Drug: Hydroxychloroquine, AzithromycinDrug: Hydroxychloroquine, ClindamycinDrug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.Drug: Interferon-Alpha2BDrug: Hydroxychloroquine, DoxycyclineDrug: Convalescent SerumDrug: RemdesivirDrug: TocilizumabDrug: LosartanDrug: Methylprednisolone
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- The Camelot Foundation
- Target Recruit Count
- 1800
- Registration Number
- NCT04349410
- Locations
- 🇺🇸
FHHI-OI-Camelot; QME, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.